Short answer
Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on August 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 references earnings-related disclosure, but the excerpt contains only exhibit liability language.
Tvardi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 references earnings-related disclosure, but the excerpt contains only exhibit liability language
- Exhibit excluded from Exchange Act Section 18 liability and Securities Act Sections 11 and 12(a)(2) liability
Item EX-99.1 · Exhibit EX-99.1
- TTI-109 healthy-volunteer data confirmed TTI-101-equivalent exposure, improved tolerability, and reductions in UC-relevant immune populations
- UC selected as lead indication; U.S. addressable market approximately $3B versus $9B globally
- TTI-109 UC trial targeted for 2027, contingent on IND clearance and additional funding
- Cash, equivalents, and short-term investments declined to $15.8M from $30.8M at December 31, 2025
- Q2 net loss $6.5M versus prior-year $4.2M net income, which included a $12.7M non-cash convertible-note gain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tvardi Therapeutics, Inc. 8-K filings
Get the next TVRD 8-K as it lands
Follow TVRD for push alerts, or ask the research agent what this filing means.